FDA Allows Public Comments on Moderna’s New mRNA Influenza ‘Pandemic’ Vaccine MFLUSIVA (mRNA-1010)
by Jon Fleetwood, Jon Fleetwood: MFLUSIVA triggers six times more severe reactions for less than 1% absolute benefit, Moderna scientists admitted last month in the New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) has scheduled a June 18, 2026 advisory committee meeting to publicly review the “safety and effectiveness” of Moderna’s […]